title: [Investigation of hepatic reserve in patients with severe liver dysfunction in the treatment of acute leukemia].
authors.forename: H
authors.initials: H
authors.lastname: Hamazaki
authors.forename: F
authors.initials: F
authors.lastname: Horiuchi
authors.forename: N
authors.initials: N
authors.lastname: Shimotsuma
authors.forename: T
authors.initials: T
authors.lastname: Fujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Tsubaki
authors.forename: K
authors.initials: K
authors.lastname: Irimajiri
authors.forename: A
authors.initials: A
authors.lastname: Horiuchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D003561:Cytarabine / Q000009:adverse effects / Q000031:analogs & derivatives; D003843:Deoxycytidine Monophosphate / Q000009:adverse effects; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008099:Liver / Q000503:physiopathology*; D008107:Liver Diseases / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
chemical_list: D003561:Cytarabine; D003843:Deoxycytidine Monophosphate; C015019:enocitabine